An interventional study of Dietary intervention in Mild Cognitive Impairment and Metabolic Syndrome, sponsored by Bristlecone Health, Inc.. Completed at 1 site in United States. Open to participants aged 35 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by Bristlecone Health, Inc. · Not applicable, Interventional, and Treatment
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts in global DNA (deoxyribonucleic acid) methylation (away from nutrient availability and toward biosynthesis) are initiated by chronic metabolic inflexibility, over-activation of the mTOR (mammalian target of rapamycin) pathway, and the deregulation of neural oxidative phosphorylation.
Nutritional epigenetics denotes gene-diet interactions and highlights the modulatory role of cellular energy status in aging and age-related diseases like cancer, cardiovascular disease (CVD), diabetes and neurodegeneration. Nutrients are epigenetic modifiers; macro and micronutrients regulate the placement and distribution of DNA histone modifiers distinguishing phenotype from genotype. Cellular energy status (AMP/ATP) modulates the regulatory mechanics of DNA methylation via the SAM (S-adenosylmethionine) methlytransferase and the SAH (S-adenosyl homocysteine) methyltransferase inhibitor index. Whole blood histamine and homocysteine levels provide additional information on the status of methylation. Hyperinsulinemia and cellular insulin resistance dysregulate nutrient sensing pathways; perpetual fed-state signaling exacerbates systemic metabolic inflexibility. Chronic elevations in insulin with long-standing impairments in glucose delivery are associated with profound changes in epigenetic expression consequent of hyper-activation of mTOR and inhibition of AMPK kinase pathways. Dietary ketosis is known to govern adaptive mitonuclear energy availability by increasing cellular reduction potential via >AMP/ATP ratio. AMPK activation adapts rRNA synthesis away from fed-state growth/storage toward energy production/release, common to fasted-states. Research suggests that induced and controlled dietary ketogenesis, a fasting mimetic, transcriptionally modifies gene expression thereby attenuating metabolic diseases.
The study will explore whether early stage memory loss (SMC \& MCI) and comorbidity of Metabolic Syndrome are symptomatic of peripheral and cerebral hypo-metabolism resultant of sustained cellular insulin resistance. The investigators will attempt to show that consequent to systemic hyperinsulinemia, mitonuclear crosstalk dysregulates the energy sensing kinases, mTOR/AMPK, thereby modifying the intra/extracellular nutrient signaling pathways. The suppression of AMPK, coupled with chronic fed-state signaling, adapts rRNA synthesis away from nutrient availability toward ATP consuming processes. Increased biosynthesis of proteins, lipids and cholesterol with concurrent inhibition of fat oxidation, energy cofactors (NAD+, SAHH) and programmed apoptosis results in the epigenetic drift of methylation toward global gene activation with region-specific silencing of key regulatory/longevity genes, SIRTs (sirtuins), FOX03 and Nrf2. This global shift in energy is marked by suppression of the SAM/SAH methylation index and correlative jumps in whole blood histamine and/or homocysteine. The study explores whether the aforementioned shift in nutrient sensing pathways modulates metabolic inflexibility via energy shunts toward cytosolic, substrate level phosphorylation via activation of PDK (pyruvate dehydrogenase kinase). An insulin resistant energy surplus (\<AMP/ATP) fosters low cellular reduction potential, which triggers mitonuclear crosstalk inhibiting oxidative ATP via PDC (pyruvate dehydrogenase complex), the regulatory gateway between anaerobic glycolysis and oxidative mitochondrial respiration. The study will attempt to show that induced and controlled dietary ketosis initiates the spontaneous/favorable release of energy ( >AMP/ATP), activating the AMPK circuitry thereby inhibiting the synthesis/storage of protein, cholesterol and lipids. Thus, a shift in cellular energy from low reduction potential (ATP/NADH) to high reduction potential (AMP/NAD+) attenuates methylation drift evidenced by marked reductions in biosynthesis: fasting lipid profile (TRI., VLDL, LDL, HDL), LP-IR score (particle concentration/size), HgA1c, fasting insulin, HOMA-IR and epigenetic modification of DNA measured by improved methylation index (>SAM/SAH) with correlating reductions in whole blood histamine and/or homocysteine. The resultant change in cerebral glucose metabolism and correlative improvement in SMC/MCI will be assessed by valid clinical measures of cognition: Montreal Cognitive Assessment (MoCA), Brief Visual Memory Test-Revised (BVMT-R) and Rey Auditory Verbal Learning Task (RAVLT) administered at baseline and weeks 2/4/6/8/10/12.
Research Question: Are selective memory complaints (SMC), mild cognitive impairments (MCI) and comorbid Metabolic Syndrome symptomatic of peripheral/cerebral insulin resistance with a resultant epigenetic drift in methylation away from energy production toward anabolic synthesis/storage, initiated and sustained by metabolic inflexibility, aerobic glycolysis and PDK inhibition of oxidative phosphorylation?
Exclusion Criteria:
Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.
Behavioral: Dietary intervention
Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat. Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week.
Behavioral: Dietary intervention
Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD).
MoCA (Montreal Cognitive Assessment)
Measures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.
Time frame: 12 weeks
NMR Lipoprofile Particle Size - Small LDL-P
Assessment of changes in Small LDL-P (total small Pattern B)
Time frame: 12 weeks
NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45
Lipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).
Time frame: 12 weeks
Fasting Triglycerides
Assessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL
Time frame: 12 weeks
Triglyceride/HDL Ratio
Assessment of changes in Triglyceride/HDL ratio over time.
Time frame: 12 weeks
Fasting Insulin
Assessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L
Time frame: 12-weeks
Fasting Glucose
Assessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL
Time frame: 12-weeks
HOMA-IR
Assessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0
Time frame: 12-weeks
HgA1c
Assessment of changes in HgA1c (Hemoglobin A1c) over time.
Time frame: 12-weeks
Weight
Assessment of changes in weight over time as measured in pounds.
Time frame: 12-weeks
Body Fat Mass (BFM)
Assessment of changes in body fat mass over time as measured in pounds.
Time frame: 12-weeks
VLDL
Assessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL
Time frame: 12-weeks
SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine)
Assessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0
Time frame: 12-weeks
SAM (S-adenosylmethionine)
Assessment of changes in SAM (S-adenosylmethionine)
Time frame: 12-weeks
SAH (S-adenosylhomocysteine)
Assessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L
Time frame: 12-weeks
Adenosine
Assessment of changes in Adenosine Range: 20-80 nmol/L
Time frame: 12-weeks
| Milestone | Experimental Group | Control Group |
|---|---|---|
| Started | 48 | 50 |
| Completed | 48 | 50 |
| Not completed | 0 | 0 |
Measures changes in cognitive function over time. Score: 30 points (maximum), 0 points (minimum). Score \>25 = normal cognitive function. Score 17-25 = mild cognitive impairment (MCI). Score \<17 = increased likelihood of Alzheimer's Disease or dementia.
| score on a scale | Experimental Group | Control Group |
|---|---|---|
| MoCA (Montreal Cognitive Assessment) | 28.38 ± 0.22 | 20.22 ± 0.22 |
Assessment of changes in Small LDL-P (total small Pattern B)
| nmol/L | Experimental Group | Control Group |
|---|---|---|
| NMR Lipoprofile Particle Size - Small LDL-P | 276.24 ± 29.25 | 588.08 ± 61.02 |
Lipoprotein insulin resistance (LP-IR) is an aggregate score of the 6 lipoprotein parameters range from 0 to 100, with higher scores indicating greater insulin resistance (IR).
| score on a scale | Experimental Group | Control Group |
|---|---|---|
| NMR Lipoprofile Particle Size - LP-IR Score (Lipoprotein Insulin Resistance) Ideal Range: <45 | 32.13 (28.87 to 35.76) | 50.66 (45.62 to 56.26) |
Assessment of changes in fasting triglycerides over time. Ranges: \< 150 mg/dL
| mg/dL | Experimental Group | Control Group |
|---|---|---|
| Fasting Triglycerides | 87.23 (76.58 to 99.35) | 131.73 (115.96 to 149.64) |
Assessment of changes in Triglyceride/HDL ratio over time.
| ratio | Experimental Group | Control Group |
|---|---|---|
| Triglyceride/HDL Ratio | 1.67 (1.41 to 1.99) | 2.69 (2.28 to 3.19) |
Assessment of changes in fasting insulin over time. Ranges: \< 2.6-11.1 mU/L
| mU/L | Experimental Group | Control Group |
|---|---|---|
| Fasting Insulin | 7.32 (6.37 to 8.42) | 11.25 (9.81 to 12.91) |
Assessment of changes in fasting glucose over time. Ranges: \< 74-100 mg/dL
| mg/dL | Experimental Group | Control Group |
|---|---|---|
| Fasting Glucose | 85.9 (82.64 to 89.30) | 109.61 (105.52 to 113.85) |
Assessment of changes in HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) over time. Ranges: \< 1.0
| units on a scale | Experimental Group | Control Group |
|---|---|---|
| HOMA-IR | 1.55 (1.32 to 1.83) | 3.05 (2.60 to 3.57) |
Assessment of changes in HgA1c (Hemoglobin A1c) over time.
| percentage of glycated hemoglobin | Experimental Group | Control Group |
|---|---|---|
| HgA1c | 5.19 (5.11 to 5.28) | 5.82 (5.73 to 5.91) |
Assessment of changes in weight over time as measured in pounds.
| pounds | Experimental Group | Control Group |
|---|---|---|
| Weight | 200.23 (189.46 to 211.62) | 210.60 (199.49 to 222.32) |
Assessment of changes in body fat mass over time as measured in pounds.
| pounds | Experimental Group | Control Group |
|---|---|---|
| Body Fat Mass (BFM) | 67.95 (62.21 to 74.21) | 79.35 (72.78 to 86.52) |
Assessment of changes in VLDL (very low density lipoprotein carrier) over time. Ranges: \< 5-40 mg/dL
| mg/dL | Experimental Group | Control Group |
|---|---|---|
| VLDL | 17.45 (15.32 to 19.87) | 26.35 (23.19 to 29.93) |
Assessment of changes in SAM/SAH (S-adenosylmethionine/S-adenosylhomocysteine) ratio Range: \>4.0
| ratio | Experimental Group | Control Group |
|---|---|---|
| SAM/SAH Ratio (S-adenosylmethionine/S-adenosylhomocysteine) | 4.938 (4.538 to 5.372) | 4.491 (4.119 to 4.896) |
Assessment of changes in SAM (S-adenosylmethionine)
| nmol/L | Experimental Group | Control Group |
|---|---|---|
| SAM (S-adenosylmethionine) | 89.784 (84.767 to 95.099) | 88.177 (83.131 to 93.529) |
Assessment of changes in SAH (S-adenosylhomocysteine) Range: 10-22 nmol/L
| nmol/L | Experimental Group | Control Group |
|---|---|---|
| SAH (S-adenosylhomocysteine) | 18.257 (17.685 to 18.847) | 19.566 (18.938 to 20.214) |
Assessment of changes in Adenosine Range: 20-80 nmol/L
| nmol/L | Experimental Group | Control Group |
|---|---|---|
| Adenosine | 23.363 (22.413 to 24.352) | 21.475 (20.581 to 22.407) |
Collected over 12-weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Group | 0/48 (0%) | 0/48 (0%) | 0/48 (0%) |
| Control Group | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Age, Categorical(Participants) | Experimental Group | Control Group | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 41 | 44 | 85 |
| >=65 years | 7 | 6 | 13 |
| Sex: Female, Male(Participants) | Experimental Group | Control Group | Total |
|---|---|---|---|
| Female | 25 | 25 | 50 |
| Male | 23 | 25 | 48 |
| Race and Ethnicity Not Collected(Participants) | Experimental Group | Control Group | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Experimental Group | Control Group | Total |
|---|---|---|---|
| United States | 48 | 50 | 98 |
| MoCA (Montreal Cognitive Assessment)(units on a scale) | Experimental Group | Control Group | Total |
|---|---|---|---|
| Least squares mean | 28.38 (27.94 to 28.81) | 20.22 (19.79 to 20.64) | 24.30 (23.50 to 25.1) |
Documents are hosted by the registry — open the source record to download them.
Plan to share: No
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristlecone Health, Inc.